A client who is newly diagnosed with diabetes insipidus is receiving a synthetic vasopressin intravenously. Which side effect of vasopressin reported by the client should the nurse report to the healthcare provider?

A) Irrigation and topical antibiotic application to wound area: While wound care is important in managing infections, obtaining cultures before initiating antibiotic therapy takes precedence to ensure appropriate treatment. Topical antibiotics may not adequately address systemic infections caused by gram-negative bacteria.
B) Monitor for signs of sodium and fluid retention: This intervention is important when administering certain antibiotics, such as those in the aminoglycoside class, but it is not the most immediate priority. Monitoring for signs of sodium and fluid retention is typically indicated after antibiotic therapy has commenced and involves assessing the client's clinical status and laboratory values for signs of electrolyte imbalance or fluid overload.
C) Wound and blood specimens for culture and sensitivity: This action is essential before initiating antibiotic therapy because it allows for the identification of the specific organism causing the infection and its susceptibility to antibiotics. This information guides the selection of the most appropriate antibiotic for targeted therapy, improving treatment efficacy and reducing the risk of antibiotic resistance.
D) Complete blood count and serum electrolytes: While monitoring laboratory values is important in the overall management of the client, obtaining cultures for culture and sensitivity testing is the priority before initiating antibiotic therapy. This step helps ensure that the chosen antibiotic is effective against the specific pathogen causing the infection.

A) Urinary output equal intake:
This assessment finding suggests that the client is voiding an amount of urine equivalent to their fluid intake, indicating effective bladder emptying. Bethanechol is a cholinergic agonist that stimulates bladder contraction, helping to improve urinary retention by promoting the expulsion of urine from the bladder. Equal urinary output and intake indicate that the bladder is adequately emptying, which is a positive response to bethanechol therapy.

B) No terminal urinary dribbling:
While the absence of terminal urinary dribbling may be an indicator of improved bladder emptying, it is not as definitive as assessing urinary output equal to intake. Terminal urinary dribbling refers to the involuntary loss of urine that occurs after completing urination due to incomplete emptying of the bladder. While its absence may suggest improved bladder emptying, it is not as reliable an indicator as measuring urinary output.

C) Denies stress incontinence:
The absence of stress incontinence, which is the involuntary loss of urine during activities that increase intra-abdominal pressure (such as coughing, sneezing, or lifting), is not directly related to the effectiveness of bethanechol for urinary retention. Bethanechol primarily targets urinary retention by stimulating bladder contraction rather than addressing stress incontinence, which involves weakness of the pelvic floor muscles.

D) Absence of xerostomia:
Xerostomia refers to dryness of the mouth due to decreased saliva production and is a common side effect of anticholinergic medications. Bethanechol, as a cholinergic agonist, may actually increase saliva production and is not typically associated with xerostomia. However, the absence of xerostomia does not directly indicate the effectiveness of bethanechol for urinary retention.